TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Share Price Today: Live Updates & Key Insights

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 share price today is $0.035999, up -2.44%. The stock opened at $0.0369 against the previous close of $0.0369, with an intraday high of $0.0369 and low of $0.0369.

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Share Price Chart

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029

us-stock
To Invest in {{usstockname}}
us-stock

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Share Price Performance

$0.035999 -0.0244(-2.44%) TVGNW at 23 Mar 2026 03:36 PM
Lowest Today 0.0369
Highest Today 0.0369
Today’s Open 0.0369
Prev. Close 0.0369
52 Week High 0.08
52 Week Low 0.03
Day’s Range: Low 0.0369 High 0.0369
52-Week Range: Low 0.03 High 0.08
1 day return -
1 Week return +1.98
1 month return -17.81
3 month return -25.0
6 month return -46.26
1 year return -42.77
3 year return -
5 year return -
10 year return -

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Institutional Holdings

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Market Status

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Fundamentals

Market Cap 0.00 M

PB Ratio 0.0

PE Ratio 0.0

Enterprise Value 0.00 M

Total Assets 3.46 M

Volume 27067

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M

Annual Profit FY25:-403581 -0.4M, FY24:null 0.0M, FY23:null 0.0M

Annual Net worth FY25:-10114380 -10.1M, FY24:-67325 -0.1M, FY23:4408361 4.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:396586 0.4M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-27225 -0.0M, Q2/2025:-290784 -0.3M, Q1/2025:-105402 -0.1M, Q3/2024:null 0.0M, Q2/2024:-99990 -0.1M

Quarterly Net worth Q3/2025:-5726812 -5.7M, Q2/2025:-5503979 -5.5M, Q1/2025:-10367061 -10.4M, Q3/2024:-5884223 -5.9M, Q2/2024:-9663447 -9.7M

About TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 & investment objective

Company Information Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Organisation

Employees 18

Industry

CEO Dr. Ryan H. Saadi M.D., M.P.H.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 FAQs

What is the share price of TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 today?

The current share price of TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 is $0.035999.

Can I buy TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 shares in India?

Yes, Indian investors can buy TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 shares by opening an international trading and demat account with Motilal Oswal.

How to buy TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 shares in India?

You can easily invest in TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 shares from India by:

Can I buy fractional shares of TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029?

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 has a market cap of $0.00 M.

In which sector does TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 belong?

TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 operates in the sector.

What documents are required to invest in TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 stocks?

To invest, you typically need:

What is the PE and PB ratio of TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029?

The PE ratio of TEVOGEN BIO HOLDINGS EQUITY WARRANT EXP 14 FEBRUARY 2029 is N/A and the PB ratio is N/A.